JP2012526558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526558A5 JP2012526558A5 JP2012511010A JP2012511010A JP2012526558A5 JP 2012526558 A5 JP2012526558 A5 JP 2012526558A5 JP 2012511010 A JP2012511010 A JP 2012511010A JP 2012511010 A JP2012511010 A JP 2012511010A JP 2012526558 A5 JP2012526558 A5 JP 2012526558A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- nos
- antigen
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 86
- 102000036639 antigens Human genes 0.000 claims description 86
- 108091007433 antigens Proteins 0.000 claims description 86
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 42
- 102000013135 CD52 Antigen Human genes 0.000 claims description 35
- 108010065524 CD52 Antigen Proteins 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims description 15
- 102000043738 human CD52 Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 3
- 229940122760 T cell stimulant Drugs 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 230000000779 depleting effect Effects 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17783709P | 2009-05-13 | 2009-05-13 | |
| US61/177,837 | 2009-05-13 | ||
| PCT/US2010/034704 WO2010132659A2 (en) | 2009-05-13 | 2010-05-13 | Anti-human cd52 immunoglobulins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014145770A Division JP2014195474A (ja) | 2009-05-13 | 2014-07-16 | 抗ヒトｃｄ５２免疫グロブリン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526558A JP2012526558A (ja) | 2012-11-01 |
| JP2012526558A5 true JP2012526558A5 (enExample) | 2014-09-04 |
| JP5894912B2 JP5894912B2 (ja) | 2016-03-30 |
Family
ID=43085579
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511010A Active JP5894912B2 (ja) | 2009-05-13 | 2010-05-13 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2014145770A Withdrawn JP2014195474A (ja) | 2009-05-13 | 2014-07-16 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2016023418A Withdrawn JP2016093194A (ja) | 2009-05-13 | 2016-02-10 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2017231850A Withdrawn JP2018029624A (ja) | 2009-05-13 | 2017-12-01 | 抗ヒトｃｄ５２免疫グロブリン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014145770A Withdrawn JP2014195474A (ja) | 2009-05-13 | 2014-07-16 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2016023418A Withdrawn JP2016093194A (ja) | 2009-05-13 | 2016-02-10 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2017231850A Withdrawn JP2018029624A (ja) | 2009-05-13 | 2017-12-01 | 抗ヒトｃｄ５２免疫グロブリン |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8617554B2 (enExample) |
| EP (3) | EP3683317A3 (enExample) |
| JP (4) | JP5894912B2 (enExample) |
| KR (5) | KR20170113704A (enExample) |
| CN (3) | CN102459628A (enExample) |
| AR (1) | AR076770A1 (enExample) |
| AU (1) | AU2010249003B2 (enExample) |
| BR (1) | BRPI1013085A2 (enExample) |
| CA (2) | CA2761800C (enExample) |
| HK (2) | HK1222682A1 (enExample) |
| IL (2) | IL216141B (enExample) |
| MX (1) | MX2011012047A (enExample) |
| MY (1) | MY160126A (enExample) |
| NZ (2) | NZ621170A (enExample) |
| RU (2) | RU2603743C2 (enExample) |
| SG (2) | SG10201608169QA (enExample) |
| TW (3) | TW201825115A (enExample) |
| WO (1) | WO2010132659A2 (enExample) |
| ZA (1) | ZA201108077B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009131712A2 (en) | 2008-04-25 | 2009-10-29 | Duke University Medical Center | Regulatory b cells and their uses |
| RU2603743C2 (ru) | 2009-05-13 | 2016-11-27 | Джензим Корпорейшн | Иммуноглобулины k cd52 человека |
| US9617343B2 (en) | 2009-05-13 | 2017-04-11 | Genzyme Corporation | Methods and compositions for treating lupus |
| WO2012088272A1 (en) * | 2010-12-21 | 2012-06-28 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| US20140193420A1 (en) | 2011-04-18 | 2014-07-10 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-itm2a antibody |
| GB201109238D0 (en) * | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| EP3559049B1 (en) | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| WO2013185165A1 (en) * | 2012-06-14 | 2013-12-19 | The Walter And Eliza Hall Institute Of Medical Research | Cd-52 antibodies and their use in determining and enhancing an immune response in a subject |
| US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
| US20150299315A1 (en) * | 2012-10-22 | 2015-10-22 | Becton, Dickinson And Company | Non-b-lineage cells capable of producing antibody |
| US10365275B2 (en) | 2013-03-12 | 2019-07-30 | Institute of Arthritis Reasearch, LLC | Immunologically active polypeptide |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| KR102042174B1 (ko) | 2013-03-29 | 2019-11-08 | 삼성전자주식회사 | 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| KR102060540B1 (ko) * | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| US20160030384A1 (en) | 2013-04-09 | 2016-02-04 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
| KR102186363B1 (ko) * | 2013-09-06 | 2020-12-04 | 삼성전자주식회사 | c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물 |
| KR102192591B1 (ko) * | 2013-09-09 | 2020-12-18 | 삼성전자주식회사 | c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물 |
| JP2018521979A (ja) | 2015-06-03 | 2018-08-09 | ボストン バイオメディカル， インコーポレイテッド | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
| KR102506091B1 (ko) | 2016-05-02 | 2023-03-07 | 프로테나 바이오사이언시즈 리미티드 | 타우 면역요법 |
| MX2018013384A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| CN109415434B (zh) | 2016-05-02 | 2022-12-30 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| WO2018112407A1 (en) | 2016-12-15 | 2018-06-21 | Duke University | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors |
| CN110546167A (zh) * | 2017-04-21 | 2019-12-06 | 建新公司 | 以抗-cd52抗体治疗多发性硬化症 |
| WO2018204546A2 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| US11396538B2 (en) | 2017-12-20 | 2022-07-26 | Radimmune Therapeutics, Inc. | Antibodies to centrin-1, methods of making, and uses thereof |
| CN113544148B (zh) * | 2018-12-19 | 2024-04-05 | 胡默波斯生物医学公司 | 中和乙型肝炎病毒的抗体和其用途 |
| FI4285929T3 (fi) | 2018-12-20 | 2025-12-30 | Humabs Biomed Sa | Hbv:n yhdistelmähoito |
| CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN109929835A (zh) * | 2019-03-27 | 2019-06-25 | 中国人民解放军第四军医大学 | 一种鼠单克隆抗体功能轻链可变区基因的扩增方法 |
| CN120775051A (zh) | 2019-05-21 | 2025-10-14 | 诺华股份有限公司 | Cd19结合分子及其用途 |
| JP7678768B2 (ja) * | 2019-07-02 | 2025-05-16 | テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド | 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 |
| WO2021223719A1 (zh) * | 2020-05-08 | 2021-11-11 | 亘喜生物科技（上海）有限公司 | 一种抗cd19抗体的抗体及其制备和应用 |
| AU2021381372A1 (en) * | 2020-11-19 | 2023-07-06 | Genzyme Corporation | Flow cytometry attenuated reporter expression (flare) multiple reporter system and methods of use thereof |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2025031965A1 (en) * | 2023-08-04 | 2025-02-13 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd52 for use in cell therapy |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPH0684377B2 (ja) | 1986-04-17 | 1994-10-26 | 協和醗酵工業株式会社 | 新規化合物ｄｃ―８８ａ及びｄｃ―８９ａ１ |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| AU618989B2 (en) * | 1988-02-12 | 1992-01-16 | British Technology Group Limited | Improvements in or relating to antibodies |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| GB9108056D0 (en) * | 1991-04-16 | 1991-06-05 | Hale Geoffrey | Synthetic antigen |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| US5269388A (en) | 1991-11-12 | 1993-12-14 | Stress-Tek, Inc. | Weighing bed |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
| ATE271557T1 (de) | 1994-04-22 | 2004-08-15 | Kyowa Hakko Kogyo Kk | Dc-89 derivat |
| US5550246A (en) | 1994-09-07 | 1996-08-27 | The Scripps Research Institute | Calicheamicin mimics |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
| JP2003514903A (ja) | 1999-11-24 | 2003-04-22 | イムノージェン インコーポレーテッド | タキサンを含有する細胞傷害薬とその治療への利用 |
| MXPA02008472A (es) | 2000-03-03 | 2004-03-26 | Cambridge Antibody Tech | Anticuerpos humanos contra la eotaxina y su uso. |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20020132983A1 (en) * | 2000-11-30 | 2002-09-19 | Junghans Richard P. | Antibodies as chimeric effector cell receptors against tumor antigens |
| AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| WO2004042032A2 (en) | 2002-11-01 | 2004-05-21 | The Ohio State University Research Foundation | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| CN1225480C (zh) * | 2002-12-18 | 2005-11-02 | 马菁 | 抗cd52单克隆抗体、其编码序列及应用 |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| JPWO2004087210A1 (ja) * | 2003-03-31 | 2006-06-29 | 麒麟麦酒株式会社 | 抗ｃｄ５２抗体による調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物 |
| WO2005017149A1 (en) | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| JP4804357B2 (ja) | 2003-11-01 | 2011-11-02 | メルク パテント ゲーエムベーハー | 改変抗ｃｄ５２抗体 |
| US20060204496A1 (en) * | 2003-11-28 | 2006-09-14 | Tetsuo Kojima | Agonist antibody against heteroreceptor |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| KR101247908B1 (ko) * | 2004-09-02 | 2013-03-26 | 제넨테크, 인크. | 항-ｆｃ-감마 ｒｉｉｂ 수용체 항체 및 그의 용도 |
| WO2006086469A2 (en) | 2005-02-08 | 2006-08-17 | Genzyme Corporation | Antibodies to tgfbeta |
| MX2007014672A (es) * | 2005-05-24 | 2008-04-08 | Avestha Gengraine Tech Pvt Ltd | Metodo recombinante para la produccion de un anticuerpo monoclonal hacia cd52 para el tratamiento de leucemia linfocitica cronica. |
| NZ564092A (en) | 2005-05-27 | 2010-05-28 | Biogen Idec Inc | TWEAK binding antibodies |
| EP1966244B1 (en) * | 2005-12-30 | 2012-03-21 | Merck Patent GmbH | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| EP2012814B1 (en) * | 2006-04-12 | 2013-05-22 | Genzyme Corporation | Methods of treating autoimmune diseases |
| DK2066352T3 (en) | 2006-09-13 | 2016-02-29 | Alcafleu Man Gmbh & Co Kg | TREATMENT OF MULTIPLE SCLEROSIS (MS) WITH CAMPATH-1H |
| NZ597915A (en) | 2007-02-28 | 2013-08-30 | Merck Sharp & Dohme | Combination therapy for treatment of immune disorders |
| JP2010530857A (ja) * | 2007-06-22 | 2010-09-16 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 神経系障害、特に感染性海綿状脳症及びアルツハイマー病を治療するためのｃｄ５２抗原に対する抗体の使用 |
| RU2603743C2 (ru) | 2009-05-13 | 2016-11-27 | Джензим Корпорейшн | Иммуноглобулины k cd52 человека |
| EP2429584A4 (en) | 2009-05-13 | 2013-02-20 | Genzyme Corp | TREATMENT PROCEDURE AND COMPOSITIONS |
| US9617343B2 (en) | 2009-05-13 | 2017-04-11 | Genzyme Corporation | Methods and compositions for treating lupus |
| KR101832201B1 (ko) | 2009-07-15 | 2018-02-28 | 에임 쎄라퓨틱스 비.브이. | 그람-양성 박테리아 특이적 결합 화합물 |
| CA3086837C (en) | 2010-07-16 | 2023-03-07 | Adimab, Llc | Libraries comprising segmental pools, and methods for their preparation and use |
| ITMI20110376A1 (it) | 2011-03-10 | 2012-09-11 | Wilic Sarl | Aerogeneratore raffreddato a fluido |
| GB201109238D0 (en) | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| CN108025083B (zh) | 2014-10-09 | 2021-09-03 | 建新公司 | 糖工程化的抗体药物缀合物 |
| CN110546167A (zh) | 2017-04-21 | 2019-12-06 | 建新公司 | 以抗-cd52抗体治疗多发性硬化症 |
-
2010
- 2010-05-13 RU RU2011150516/10A patent/RU2603743C2/ru not_active IP Right Cessation
- 2010-05-13 NZ NZ621170A patent/NZ621170A/en not_active IP Right Cessation
- 2010-05-13 SG SG10201608169QA patent/SG10201608169QA/en unknown
- 2010-05-13 CN CN2010800312662A patent/CN102459628A/zh active Pending
- 2010-05-13 TW TW106123171A patent/TW201825115A/zh unknown
- 2010-05-13 BR BRPI1013085-3A patent/BRPI1013085A2/pt not_active IP Right Cessation
- 2010-05-13 CN CN201910228216.6A patent/CN110016081A/zh active Pending
- 2010-05-13 AU AU2010249003A patent/AU2010249003B2/en not_active Ceased
- 2010-05-13 MY MYPI2011005455A patent/MY160126A/en unknown
- 2010-05-13 JP JP2012511010A patent/JP5894912B2/ja active Active
- 2010-05-13 KR KR1020177026871A patent/KR20170113704A/ko not_active Ceased
- 2010-05-13 CA CA2761800A patent/CA2761800C/en active Active
- 2010-05-13 KR KR1020117029662A patent/KR101537840B1/ko not_active Expired - Fee Related
- 2010-05-13 KR KR1020157036932A patent/KR20160005143A/ko not_active Withdrawn
- 2010-05-13 AR ARP100101677A patent/AR076770A1/es not_active Application Discontinuation
- 2010-05-13 EP EP19214547.2A patent/EP3683317A3/en not_active Withdrawn
- 2010-05-13 US US13/320,019 patent/US8617554B2/en active Active
- 2010-05-13 NZ NZ596384A patent/NZ596384A/en not_active IP Right Cessation
- 2010-05-13 MX MX2011012047A patent/MX2011012047A/es active IP Right Grant
- 2010-05-13 KR KR1020147020065A patent/KR20140102764A/ko not_active Withdrawn
- 2010-05-13 TW TW104144762A patent/TWI614267B/zh not_active IP Right Cessation
- 2010-05-13 SG SG2011083847A patent/SG176060A1/en unknown
- 2010-05-13 WO PCT/US2010/034704 patent/WO2010132659A2/en not_active Ceased
- 2010-05-13 EP EP15191351.4A patent/EP2998405B1/en active Active
- 2010-05-13 RU RU2016142225A patent/RU2016142225A/ru not_active Application Discontinuation
- 2010-05-13 EP EP10775530A patent/EP2429582A4/en not_active Withdrawn
- 2010-05-13 CA CA2939492A patent/CA2939492C/en active Active
- 2010-05-13 KR KR1020167022759A patent/KR20160103160A/ko not_active Ceased
- 2010-05-13 TW TW099115371A patent/TWI529247B/zh not_active IP Right Cessation
- 2010-05-13 CN CN201410379748.7A patent/CN104231084B/zh active Active
-
2011
- 2011-11-03 ZA ZA2011/08077A patent/ZA201108077B/en unknown
- 2011-11-03 IL IL216141A patent/IL216141B/en not_active IP Right Cessation
-
2012
- 2012-09-10 HK HK16110806.5A patent/HK1222682A1/en unknown
-
2013
- 2013-11-26 US US14/091,083 patent/US20140341910A1/en not_active Abandoned
-
2014
- 2014-07-16 JP JP2014145770A patent/JP2014195474A/ja not_active Withdrawn
-
2015
- 2015-06-18 HK HK15105820.8A patent/HK1205152A1/xx unknown
- 2015-09-24 US US14/864,736 patent/US20160208010A1/en not_active Abandoned
-
2016
- 2016-02-10 JP JP2016023418A patent/JP2016093194A/ja not_active Withdrawn
-
2017
- 2017-12-01 JP JP2017231850A patent/JP2018029624A/ja not_active Withdrawn
-
2018
- 2018-10-28 IL IL262639A patent/IL262639A/en unknown
-
2019
- 2019-04-10 US US16/380,389 patent/US20200040091A1/en not_active Abandoned
-
2021
- 2021-03-03 US US17/191,440 patent/US11945874B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526558A5 (enExample) | ||
| RU2016142225A (ru) | Иммуноглобулины к cd52 человека | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| EP3476399B1 (en) | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof | |
| TWI854953B (zh) | 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法 | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| CN113454119B (zh) | 抗btla抗体 | |
| CN116239698A (zh) | 双功能融合蛋白及其医药用途 | |
| JP2016513467A5 (enExample) | ||
| JP2017537082A5 (enExample) | ||
| CA3064298A1 (en) | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof | |
| CA3207791A1 (en) | Anti-cd112r antibody and use thereof | |
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| JP2013519690A5 (enExample) | ||
| TW202529810A (zh) | 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體 | |
| CN116847863A (zh) | 抗人cd22的单克隆抗体及其用途 | |
| TW202523701A (zh) | 用於治療癌症之ｓｉｒｐ抗體 | |
| JPWO2021068841A5 (enExample) | ||
| WO2022228545A1 (en) | Antibodies and variants thereof against human 4-1bb | |
| US20230042316A1 (en) | Monoclonal antibodies that target human cd47 protein | |
| US20240084012A1 (en) | Anti-pd-1/cd47 bispecific antibody and use thereof | |
| WO2024218650A1 (en) | Lilrb1 and lilrb2 antibodies and methods of use thereof | |
| WO2023228082A1 (en) | Anti-tnfr2 antibodies and methods of use thereof | |
| HK40121520A (zh) | 抗-tnfr2抗体及其使用方法 | |
| JP2025084100A (ja) | 抗ｔｎｆｒ２抗体およびその使用の方法 |